Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015

Nenhuma Miniatura disponível
Arquivos
art_FEIGIN_Global_regional_and_national_burden_of_neurological_disorders_2017.PDF (44.94 KB)
Citações na Scopus
1575
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
FEIGIN, Valery L.
ABAJOBIR, Amanuel Alemu
ABATE, Kalkidan Hassen
ABD-ALLAH, Foad
ABDULLE, Abdishakur M.
ABERA, Semaw Ferede
ABYU, Gebre Yitayih
AHMED, Muktar Beshir
AICHOUR, Amani Nidhal
AICHOUR, Ibtihel
Citação
LANCET NEUROLOGY, v.16, n.11, p.877-897, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Comparable data on the global and country-specific burden of neurological disorders and their trends are crucial for health-care planning and resource allocation. The Global Burden of Diseases, Injuries, and Risk Factors (GBD) Study provides such information but does not routinely aggregate results that are of interest to clinicians specialising in neurological conditions. In this systematic analysis, we quantified the global disease burden due to neurological disorders in 2015 and its relationship with country development level. Methods We estimated global and country-specific prevalence, mortality, disability-adjusted life-years (DALYs), years of life lost (YLLs), and years lived with disability (YLDs) for various neurological disorders that in the GBD classification have been previously spread across multiple disease groupings. The more inclusive grouping of neurological disorders included stroke, meningitis, encephalitis, tetanus, Alzheimer's disease and other dementias, Parkinson's disease, epilepsy, multiple sclerosis, motor neuron disease, migraine, tension-type headache, medication overuse headache, brain and nervous system cancers, and a residual category of other neurological disorders. We also analysed results based on the Socio-demographic Index (SDI), a compound measure of income per capita, education, and fertility, to identify patterns associated with development and how countries fare against expected outcomes relative to their level of development. Findings Neurological disorders ranked as the leading cause group of DALYs in 2015 (250.7 [95% uncertainty interval (UI) 229.1 to 274.7] million, comprising 10.2% of global DALYs) and the second-leading cause group of deaths (9.4 [9.1 to 9.7] million], comprising 16.8% of global deaths). The most prevalent neurological disorders were tensiontype headache (1505 9 [UI 1337.3 to 1681.6 million cases]), migraine (958.8 [872.1 to 1055.6] million), medication overuse headache (58.5 [50.8 to 67.4 million]), and Alzheimer's disease and other dementias (46.0 [40.2 to 52.7 million]). Between 1990 and 2015, the number of deaths from neurological disorders increased by 36.7%, and the number of DALYs by 7.4%. These increases occurred despite decreases in age-standardised rates of death and DALYs of 26.1% and 29.7%, respectively; stroke and communicable neurological disorders were responsible for most of these decreases. Communicable neurological disorders were the largest cause of DALYs in countries with low SDI. Stroke rates were highest at middle levels of SDI and lowest at the highest SDI. Most of the changes in DALY rates of neurological disorders with development were driven by changes in YLLs. Interpretation Neurological disorders are an important cause of disability and death worldwide. Globally, the burden of neurological disorders has increased substantially over the past 25 years because of expanding population numbers and ageing, despite substantial decreases in mortality rates from stroke and communicable neurological disorders. The number of patients who will need care by clinicians with expertise in neurological conditions will continue to grow in coming decades. Policy makers and health-care providers should be aware of these trends to provide adequate services.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/24181
Referências
  1. Aarli JA, 2006, NEUR DIS PUBL HLTH C
  2. Alla S, 2014, NEUROEPIDEMIOLOGY, V42, P154, DOI 10.1159/000358174
  3. American Psychiatric Association, 2000, DIAGN STAT MAN MENT
  4. Arnao V, 2016, INT J STROKE, V11, P287, DOI 10.1177/1747493016632245
  5. Banerjee PN, 2009, EPILEPSY RES, V85, P31, DOI 10.1016/j.eplepsyres.2009.03.003
  6. Cheung RTF, 2000, HEADACHE, V40, P473, DOI 10.1046/j.1526-4610.2000.00071.x
  7. Chio A, 2013, NEUROEPIDEMIOLOGY, V41, P118, DOI 10.1159/000351153
  8. Dahlrot RH, 2016, ACTA ONCOL, V55, P91, DOI 10.3109/0284186X.2015.1115123
  9. de Robles P, 2015, NEURO-ONCOLOGY, V17, P776, DOI 10.1093/neuonc/nou283
  10. Divino-Goes KG, 2007, BRAZ J MED BIOL RES, V40, P1681, DOI 10.1590/S0100-879X2007001200012
  11. Eskandarieh S, 2016, NEUROEPIDEMIOLOGY, V46, P209, DOI 10.1159/000444019
  12. Ezejimofor MC, 2016, J NEUROL SCI, V364, P68, DOI 10.1016/j.jns.2016.03.016
  13. Feigin VL, 2016, NAT REV NEUROL, V12, P501, DOI 10.1038/nrneurol.2016.107
  14. Feigin VL, 2009, LANCET NEUROL, V8, P355, DOI 10.1016/S1474-4422(09)70025-0
  15. Fernandez-de-las-Penas C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110530
  16. Fiest KM, 2016, CAN J NEUROL SCI, V43, pS3, DOI 10.1017/cjn.2016.18
  17. Flaxman AD, 2015, INTEGRATIVE METAREGR
  18. Foreman KJ, 2012, POPUL HEALTH METR, V10, DOI 10.1186/1478-7954-10-1
  19. Greenberg DP, 2009, PEDIATR INFECT DIS J, V28, P521, DOI 10.1097/INF.0b013e318199d2fc
  20. Grytten N, 2015, ACTA NEUROL SCAND, V132, P29, DOI 10.1111/ane.12428
  21. Halperin SA, 2012, VACCINE, V30, pB26, DOI 10.1016/j.vaccine.2011.12.032
  22. Hirsch L, 2016, NEUROEPIDEMIOLOGY, V46, P292, DOI 10.1159/000445751
  23. The International Headache Society, INT CLASS HEAD DIS
  24. Janca A, 2006, J NEUROL SCI, V247, P29, DOI 10.1016/j.jns.2006.03.003
  25. Kantarci O, 2006, CURR OPIN NEUROL, V19, P248, DOI 10.1097/01.wco.0000227033.47458.82
  26. Kassebaum NJ, 2016, LANCET, V388, P1603, DOI 10.1016/S0140-6736(16)31460-X
  27. Koch-Henriksen N, 2010, LANCET NEUROL, V9, P520, DOI 10.1016/S1474-4422(10)70064-8
  28. KURTZKE JF, 1993, CLIN MICROBIOL REV, V6, P382
  29. Lopez AL, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003630
  30. Logroscino G, 2008, J NEUROL NEUROSUR PS, V79, P6, DOI 10.1136/jnnp.2006.104828
  31. Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
  32. Luepker RV, 2012, CIRCULATION, V126, P1852, DOI 10.1161/CIRCULATIONAHA.112.098517
  33. Lyngberg AC, 2005, EUR J EPIDEMIOL, V20, P243, DOI 10.1007/s10654-004-6519-2
  34. Mallick I H, 2004, Int J Surg, V2, P109, DOI 10.1016/S1743-9191(06)60056-3
  35. Mehta P, 2014, MMWR SURVEILL SUMM, V63, P1
  36. Muangpaisan W, 2009, J EPIDEMIOL, V19, P281, DOI 10.2188/jea.JE20081034
  37. Murray CJL, 2012, LANCET, V380, P2063, DOI 10.1016/S0140-6736(12)61899-6
  38. Murray CJL, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-27
  39. Murray C. J. L., 1996, GLOBAL BURDEN DIS CO
  40. Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2
  41. Ngugi AK, 2011, NEUROLOGY, V77, P1005, DOI 10.1212/WNL.0b013e31822cfc90
  42. Ngugi AK, 2010, EPILEPSIA, V51, P883, DOI 10.1111/j.1528-1167.2009.02481.x
  43. Owolabi M, 2016, BMJ GLOB HEALTH, V1, DOI 10.1136/bmjgh-2016-000105
  44. Preux PM, 2005, LANCET NEUROL, V4, P21, DOI 10.1016/S1474-4422(04)00963-9
  45. Prince M, 2016, ALZHEIMERS RES THER, V8, DOI 10.1186/s13195-016-0188-8
  46. Pringsheim T, 2014, MOVEMENT DISORD, V29, P1583, DOI 10.1002/mds.25945
  47. Rothwell PM, 2004, LANCET, V363, P1925, DOI 10.1016/S0140-6736(04)16405-2
  48. Salomon JA, 2015, LANCET GLOB HEALTH, V3, pE712, DOI 10.1016/S2214-109X(15)00069-8
  49. Sander JW, 2016, NAT REV NEUROL, V12, DOI 10.1038/nrneurol.2016.32
  50. Stevens GA, 2016, LANCET, V388, pE19, DOI 10.1016/S0140-6736(16)30388-9
  51. Stevens GA, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002056
  52. Stovner LJ, 2007, CEPHALALGIA, V27, P193, DOI 10.1111/j.1468-2982.2007.01288.x
  53. Thrift AG, 2017, INT J STROKE, V12, P13, DOI 10.1177/1747493016676285
  54. Tse LA, 2012, PUBLIC HEALTH, V126, P960, DOI 10.1016/j.puhe.2012.07.010
  55. Turnbull F, 2001, NZ PUBLIC HLTH REPOR, V8, P57
  56. Ukraintseva S, 2006, STROKE, V37, P1155, DOI 10.1161/01.STR.0000217971.88034.e9
  57. Vazquez MC, 2008, NEUROEPIDEMIOLOGY, V30, P105, DOI 10.1159/000120023
  58. Vetvik KG, 2017, LANCET NEUROL, V16, P76, DOI 10.1016/S1474-4422(16)30293-9
  59. Vos T, 2016, LANCET, V388, P1545, DOI 10.1016/S0140-6736(16)31678-6
  60. Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4
  61. Vukovic V, 2010, NEUROEPIDEMIOLOGY, V35, P59, DOI 10.1159/000310940
  62. Waisbord S, 2005, WHY INVEST COMMUNICA
  63. Wallin MT, 2004, ANN NEUROL, V55, P65, DOI 10.1002/ana.10788
  64. Wang HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1
  65. Westergaard ML, 2014, CEPHALALGIA, V34, P409, DOI 10.1177/0333102413512033
  66. Yi X, 2017, VACCINE, V35, P1227, DOI 10.1016/j.vaccine.2017.01.015
  67. Zivadinov R, 2003, NEUROEPIDEMIOLOGY, V22, P65, DOI 10.1159/000067107

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HU
Artigos e Materiais de Revistas Científicas - LIM/20
Artigos e Materiais de Revistas Científicas - LIM/51
Artigos e Materiais de Revistas Científicas - ODS/03